Unicycive Therapeutics Faces Class Action Over Securities Violations - Investors Encouraged to Act

Unicycive Therapeutics, Inc. Faces A Class Action Lawsuit

In a significant legal development, Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is currently facing a class action lawsuit spearheaded by the DJS Law Group, focusing on alleged violations of the Securities Exchange Act of 1934. Investors are encouraged to examine their rights and consider joining the lawsuit to seek potential recovery for their losses.

Lawsuit Details

The ongoing legal action revolves around claims that Unicycive made false and misleading statements surrounding its product pipeline and its potential for regulatory success. Specifically, the lawsuit pertains to the company's treatment, OLC, designed to manage hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis. Unicycive's optimism regarding FDA approval has come under scrutiny, with allegations indicating that their public statements were materially deceptive and did not accurately reflect the realities of the situation.

The lead plaintiff's class period spans from March 29, 2024, to June 27, 2025. Investors who purchased shares during this timeframe are particularly relevant to the case and are encouraged to reach out for participation opportunities. The deadline for filing is set for October 14, 2025.

Reasons to Join the Class Action

For shareholders who faced financial losses due to purchasing shares while misleading information was disseminated, joining the class action can be a vital step towards recovery. Although being appointed as a lead plaintiff is not a prerequisite to participating in the recovery process, it could indicate a more prominent role in the legal proceedings. Enrolled participants will gain access to monitoring software that provides regular updates about the case's progress, ensuring they remain informed without incurring any costs.

The Role of DJS Law Group

The DJS Law Group has a robust reputation in the realm of securities class actions. Their mission is to optimize investor returns through diligent representation and legal advocacy. They specialize in a variety of complex cases, including corporate governance disputes and strategic appraisals. The firm represents various sophisticated clients, including hedge funds and other financial entities, making them well-positioned to navigate the complexities of this class action lawsuit.

Investors who join the case not only seek potential financial recovery but also contribute to holding companies accountable for their commitments and disclosures.

Next Steps for Investors

Shareholders impacted by the alleged misrepresentation are strongly urged to contact the DJS Law Group. Each investor can expect to be enrolled in a portfolio monitoring system, ensuring they receive the most current information as the case progresses. For those concerned about costs, it is important to note that there are no fees to participate unless the lawsuit achieves a successful outcome.

Conclusion

As the situation with Unicycive Therapeutics unfolds, investors are advised to act promptly. Engaging with the lawsuit could not only provide an opportunity for financial restitution but also reinforce the significance of truthful disclosure in the securities markets. For further information or to initiate contact, the DJS Law Group provides clear and accessible channels for potential class members.

In light of this unfolding scenario, shareholders should continue to monitor their investments and remain vigilant about their rights as investors.

Contact Information
David J. Schwartz
DJS Law Group
Address: 274 White Plains Road, Suite 1, Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]